Treatment of Mild Enteropathy Celiac Disease (TMCD)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The main purpose of this study is to evaluate the natural history of gluten sensitivity in endomysial antibody positive adults with celiac disease suspicion, who were found to have a only mild enteropathy (Marsh I-II) in the small-bowel mucosa. The investigators hypothesize that these subject are indeed gluten-sensitive, as measured by clinical, serological and histological indicators. If this would be the case, the current diagnostic criteria for celiac disease might need re-evaluation.
| Condition | Intervention |
|---|---|
|
Celiac Disease |
Dietary Supplement: Gluten-free diet |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Treatment of Mild Enteropathy Celiac Disease |
- Small-Bowel mucosal morphology [ Time Frame: one year ] [ Designated as safety issue: No ]
- Endomysial antibodies, tissue transglutaminase antibodies, Small-Bowel mucosal inflammation, clinical symptoms, laboratory parameters, bone mineral density. [ Time Frame: One year ] [ Designated as safety issue: No ]
| Enrollment: | 73 |
| Study Start Date: | March 2003 |
| Study Completion Date: | December 2008 |
| Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: A1
Gluten-containing diet
|
|
|
Active Comparator: A2
Gluten-free diet
|
Dietary Supplement: Gluten-free diet
Gluten containing foods removed from diet
Other Name: No other names
|
Detailed Description:
The current diagnostic criteria of celiac disease require small-bowel mucosal villous atrophy with crypt hyperplasia (Marsh III). However, the mucosal damage develops gradually and the patients may have clinical symptoms and endomysial antibodies before the development of villous atrophy.
The main purpose of this study is to evaluate the natural history of gluten sensitivity in endomysial antibody positive adults with celiac disease suspicion, who were found to have a only mild enteropathy (Marsh I-II) in the small-bowel mucosa. We hypothesize that these subject are indeed gluten-sensitive, as measured by clinical, serological and histological indicators. If this would be the case, the current diagnostic criteria for celiac disease might need re-evaluation.
Eligibility| Ages Eligible for Study: | 16 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Celiac disease suspicion
- Positive endomysial antibodies
- At least Marsh I -type small-bowel mucosal lesion
Exclusion Criteria:
- Earlier celiac disease diagnosis
- Consuming oral corticosteroids or immune suppressants
Contacts and Locations| Finland | |
| University of Tampere | |
| Tampere, Finland, 33014 | |
| Principal Investigator: | Katri Kaukinen, MD, PhD | University of Tampere |
More Information
No publications provided
| Responsible Party: | Katri Kaukinen MD, PhD, University of Tampere, Tampere University Hospital |
| ClinicalTrials.gov Identifier: | NCT00628823 History of Changes |
| Other Study ID Numbers: | SA-115376 |
| Study First Received: | February 24, 2008 |
| Last Updated: | December 3, 2008 |
| Health Authority: | Finland: Ministry of Social Affairs and Health |
Keywords provided by University of Tampere:
|
Celiac Disease Endomysial antibodies Mild enteropathy Treatment Gluten-free diet |
Additional relevant MeSH terms:
|
Celiac Disease Intestinal Diseases Malabsorption Syndromes |
Gastrointestinal Diseases Digestive System Diseases Metabolic Diseases |
ClinicalTrials.gov processed this record on June 18, 2013